ERBB2 and non-small cell lung carcinoma: The activity of T-DXd in HER2-mutant non-small cell lung cancer (NSCLC) patients has been investigated in the DESTINY-Lung01 trial, a multicenter, international, phase 2 study, showing durable responses in this subset of pretreated patients [27].